Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis

Autoimmunity

Volumn 39, Issue 4, 2006, Pages 341-348

  Montano Loza, Aldo ^a   Czaja, Albert J ^a   Carpenter, Herschel A ^b   Piette, Andrea ^c   Murphy, Daniel ^c   Shums, Zakera ^c   Burlingame, Rufus ^c   Norman, Gary L ^c  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

^c INOVA DIAGNOSTICS INC   (United States)

Author keywords

Autoantibodies; Autoimmune phenotype; Cyclic citrullinated peptide

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; DEATH; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROGNOSIS; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; ASPARTATE AMINOTRANSFERASES; AUTOANTIBODIES; AZATHIOPRINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS, AUTOIMMUNE; HLA-DR3 ANTIGEN; HLA-DR4 ANTIGEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDNISONE; RETROSPECTIVE STUDIES;

EID: 33747000422     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930600783348     Document Type: Article

References (35)

1. Czaja, AJ. (2005) Autoantibodies in autoimmune liver disease Adv Clin Chem, 40, pp. 127-164.
2. Czaja, AJ and Donaldson, PT and Lohse, AW. (2002) Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis Am J Gastroenterol, 97, pp. 413-419.
3. Czaja, AJ and Carpenter, HA and Santrach, PJ and Moore, SB. (1993) Significance of HLA DR4 in type I autoimmune hepatitis Gastroenterology, 105, pp. 1502-1507.
4. Fusconi, M and Vannini, A and Dall'Aglio, AC and Pappas, G and Cassani, F and Ballardini, G and Frisoni, M and Grassi, A and Bianchi, FB and Zauli, D. (2005) Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis Aliment Pharmacol Ther, 22, pp. 951-955.
5. Rantapaa-Dahlqvist, S and de Jong, BA and Berglin, E and Hallman, G and Wadell, G and Stenlund, H and Sundin, U and van Venrooij, WJ. (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis Arthritis Rheum, 48, pp. 2701-2705.
6. van Gaalen, FA and Linn-Rasker, SP and van Venrooij, WJ and de Jong, BA and Breedveld, FC and Verweij, CL and Toes, RE and Huizinga, TW. (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study Arthritis Rheum, 50, pp. 709-715.
7. Raza, K and Breese, M and Nightingale, P and Kumar, K and Potter, T and Carruthers, DM and Situnayake, D and Gordon, C and Buckley, CD and Salmon, M and Kitas, GD. (2005) Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis J Rheumatol, 32, pp. 231-238.
8. Czaja, AJ and Carpenter, HA. (2006) Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly Hepatology, 43, pp. 532-538.
9. Kroot, EJ and de Jong, BAW and van Leeuwen, MA and Swinkles, H and van den Hoogen, FHJ and van't Hof, M and van de Putte, LB and van Rijswijk, MH and van Venrooij, WJ and van Riel, PL. (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis Arthritis Rheum, 43, pp. 1831-1835.
10. Vossenaar, ER and van Venrooij, WJ. (2004) Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis Clin Appl Immunol Rev, 4, pp. 239-262.
11. van der Helm-van Mill, AHM and Verpoort, KN and Breedveld, FC and Toes, REM and Huizinga, TWJ. (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis Arthritis Res Ther, 7, pp. R949-R958.
12. Vallbracht, I and Helmke, K. (2005) Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis Autoimmunity Rev, 4, pp. 389-394.
13. Vossenaar, ER and Nijenhuis, S and van Helsen, MM and van der Heijden, A and Senshu, T and van den Berg, WB and van Venrooij, WJ and Joosten, LA. (2003) Citrullination of synovial proteins in murine models of rheumatoid arthritis Arthritis Rheum, 48, pp. 2489-2500.
14. Lundberg, K and Nijenhuis, S and Vossenaar, ER and Palmblad, K and van Ventooij, WJ and Klareskog, L and Zendman, AJ and Harris, HE. (2005) Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity Arthritis Res Ther, 7, pp. R458-R467.
15. Alvarez, F and Berg, PA and Bianchi, FB and Bianchi, L and Burroughs, AK and Cancado, EL and Chapman, RW and Cooksley, WGE and Czaja, AJ and Desmet, VJ and Donaldson, PT and Eddleston, ALWF and Fainboim, L and Heathcote, J and Homberg, J-C and Hoofnagle, JH and Kakumu, S and Krawitt, EL and Mackay, IR and MacSween, RNM and Maddrey, WC and Manns, MP and McFarlane, IG and Meyer zum Buschenfelde, K-H and Mieli-Vergani, G and Nakanuma, Y and Nishioka, M and Penner, E and Porta, G and Portmann, BC and Reed, WD and Rodes, J and Schalm, SW and Scheuer, PJ and Schrumpf, E and Seki, T and Toda, G and Tsuji, T and Tygstrup, N and Vergani, D and Zeniya, M. (1999) International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis J Hepatol, 31, pp. 929-938.
16. Czaja, AJ and Freese, DK. (2002) Diagnosis and treatment of autoimmune hepatitis Hepatology, 36, pp. 479-497.
17. Czaja, AJ and Manns, MP. (1995) The validity and importance of subtypes of autoimmune hepatitis: A point of view Am J Gastroenterol, 90, pp. 1206-1211.
18. Arnett, FC and Edworthy, SM and Bloch, DA and McShane, DJ and Fries, JF and Cooper, NS and Healey, LA and Kaplan, SR and Liang, MH and Luthra, HS and (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum, 31, pp. 315-324.
19. Czaja, AJ and Cassani, F and Cataleta, M and Valentini, P and Bianchi, FB. (1996) Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis Hepatology, 24, pp. 1068-1073.
20. Czaja, AJ and Cassani, F and Cataleta, M and Valentini, P and Bianchi, FB. (1997) Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis Dig Dis Sci, 42, pp. 1688-1696.
21. Homburger, HA and Cahen, YD and Griffiths, J and Jacob, GL. (1998) Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods Arch Pathol Lab Med, 122, pp. 993-999.
22. Czaja, AJ and Manns, MP and Homburger, HA. (1992) Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis Gastroenterology, 103, pp. 1290-1295.
23. Czaja, AJ and Carpenter, HA. (1993) Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis Gastroenterology, 105, pp. 1824-1832.
24. DiMagno, EP and Corle, D and O'Brien, JF and Masnyk, IJ and Go, VLW and Aamodt, R. (1989) Effect of long-term freezer storage, thawing, and refreezing on selected constituents of serum Mayo Clin Proc, 64, pp. 1226-1234.
25. Czaja, AJ and Wolf, AM and Baggenstoss, AH. (1981) Laboratory assessment of severe chronic active liver disease (CALD): Correlation of serum transaminase and gamma globulin levels with histologic features Gastroenterology, 80, pp. 687-692.
26. Czaja, AJ and Shums, Z and Norman, GL. (2004) Nonstandard antibodies as prognostic markers in autoimmune hepatitis Autoimmunity, 37, pp. 195-201.
27. Czaja, AJ and Carpenter, HA and Santrach, PJ and Moore, SB. (1993) Genetic predispositions for the immunological features of chronic active hepatitis Hepatology, 18, pp. 816-822.
28. Vossenaar, ER and Zendman, AJW and vanVenrooij, WJ and Pruijn, G. (2003) PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease Bioessays, 25, pp. 1106-1118.
29. Neubauer, K and Knittel, T and Armbrust, T and Ramadori, G. (1995) Accumulation and cellular localization of fibrinogen/fibrin during short-term and long-term rat liver injury Gastroenterology, 108, pp. 1124-1135.
30. Czaja, AJ and Dos Santos, RM and Porto, A and Santrach, PJ and Moore, SB. (1998) Immune phenotype of chronic liver disease Dig Dis Sci, 43, pp. 2149-2155.
31. Friedman, SL. (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury J Biol Chem, 275, pp. 2247-2250.
32. Czaja, AJ and Carpenter, HA. (2004) Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis J Hepatol, 40, pp. 644-650.
33. Irigoyen, P and Lee, AT and Wener, MH and Li, W and Kern, M and Batliwalla, F and Lum, RF and Massarotti, E and Weisman, M and Bombardier, C and Remmer, EF and Kastner, DL and Seldin, MF and Criswell, LA and Gregersen, PK. (2005) Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Contrasting effects of HLA-DR3 and the shared epitope alleles Arthritis Rheum, 52, pp. 3813-3818.
34. Linn-Rasker, SP and van der Helm-van Mil, AH and Van Gaalen, FA and Kloppenburg, M and de Vries, R and le Cessie, S and Breedveld, FC and Toes, RE and Huizinga, TW. (2006) Smoking is a risk factor for anti-CCP antibodies only in RA patients that carry HLA-DRB1 shared epitope alleles Ann Rheum Dis, 65, pp. 366-371.
35. Donaldson, PT and Doherty, DG and Hayllar, KM and McFarlane, IG and Johnson, PJ and Williams, R. (1991) Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors Hepatology, 13, pp. 701-706.